Over 150 clinical sites now activated in RESPONSE Phase 3 clinical trial
Results from a 52-week, open-label phase 2 study of seladelpar in patients with PBC published in the
Conference call and webcast today at
Recent Corporate Highlights
- Moving towards completion of enrollment in RESPONSE, a 52-week, placebo-controlled, randomized, global, Phase 3 registrational study evaluating the safety and efficacy of seladelpar in patients with PBC. This study is targeting enrollment of 180 patients who have an inadequate response to, or intolerance to, ursodeoxycholic acid, in a 2:1 randomization to oral, once daily seladelpar 10 mg or placebo. The primary outcome measure is the responder rate at 52 weeks. A responder is defined as a patient who achieves an alkaline phosphatase level < 1.67 times the upper limit of normal with at least a 15% decrease from baseline and has a normal level of total bilirubin. Additional key outcomes of efficacy will compare the rate of normalization of alkaline phosphatase at 52 weeks and the level of pruritus at 6-months for patients with moderate to severe pruritus at baseline assessed by a numerical rating scale recorded with an electronic diary. To date we have over 150 sites activated across 26 countries.
- Continued strong enrollment in ASSURE, an open-label, long-term study of seladelpar in patients with PBC intended to collect additional long-term safety data to support registration. In April, we successfully rolled over patients completing RESPONSE into ASSURE. Together with patients that entered into ASSURE from prior studies with seladelpar, there are now approximately 140 patients in this study taking daily seladelpar.
- Supported enrollment efforts in a Phase 2a proof-of-pharmacology study to evaluate the potential for MBX-2982, a GPR119 agonist, to prevent hypoglycemia in patients with type 1 diabetes. The study is being conducted by the
AdventHealth Translational Research Institute inOrlando, Florida and fully funded byThe Leona M. and Harry B. Helmsley Charitable Trust with CymaBay retaining full rights to MBX-2982. - Published results from Phase 2, 52-week study of seladelpar in patients with primary biliary cholangitis (PBC) in the
Journal of Hepatology . This 52-week, phase 2, dose-ranging, open-label study examined the efficacy and safety of seladelpar in PBC patients who were receiving or intolerant to first-line therapy with ursodeoxycholic acid., The results included:- An interim primary efficacy analysis of ALP change from baseline at Week 8 found that seladelpar treatment provided 26%, 33%, and 41% reductions for the 2 mg, 5 mg and 10 mg doses, respectively (all p<0.005).
- Responses were maintained or improved at Week 52, which included dose escalation in 91% and 80% of the 2 mg and 5 mg cohorts, respectively.
- At Week 52, the composite biochemical response (ALP <1.67×ULN, ≥15% ALP decrease from baseline, and normal total bilirubin) rates were 64%, 53%, and 67%, and ALP normalization rates were 9%, 13%, and 33% in the 2 mg, 5 mg, and 10 mg cohorts, respectively.
- The pruritus visual analog scale score decreased in the 5 mg and 10 mg cohorts.
- There were no treatment-related serious adverse events (AEs), and 4 patients discontinued due to AEs.
- Expanded the Board of Directors to include Dr. Éric Lefebvre, the Chief Medical Officer of Pliant Therapeutics. Prior to joining Pliant,
Dr. Lefebvre served as the Vice President of Research and Development of Allergan plc and before that was Chief Medical Officer ofTobira Therapeutics, Inc. Dr. Lefebvre also led global clinical development and global medical affairs atJanssen Pharmaceuticals for 10 years prior to starting his pharmaceutical career at GlaxoSmithKline Canada. - Received
$25 million of funding inJanuary 2022 from Abingworth through a non-dilutive financing agreement for the development of seladelpar, which was executed inJuly 2021 .$75 million has been received to date through the financing agreement. CymaBay also has an option to receive an additional$25 million after the completion of enrollment of the RESPONSE clinical trial. - Held
$193.4 million in cash, cash equivalents and investments as ofMarch 31, 2022 . We believe that cash and investments on hand, together with committed capital available through the development financing agreement with Abingworth, is sufficient to fund CymaBay’s operating plan through 2023.
First Quarter Ended
- Research and development expenses for the three months ended
March 31, 2022 and 2021 were$18.4 million and$12.4 million , respectively. Research and development expenses in the three months endedMarch 31, 2022 were higher than the corresponding period in 2021 primarily due to an increase in clinical trial activities associated with the ongoing late-stage development of seladelpar in PBC. In particular, cost increases were primarily driven by an expansion of our site activation, patient enrollment, and other clinical trial activities associated with RESPONSE and ASSURE, our two active global late-stage clinical trials in PBC. - General and administrative expenses for the three months ended
March 31, 2022 and 2021 were$6.1 million and$5.2 million , respectively. General and administrative expenses in the three months endedMarch 31, 2022 were higher than the corresponding period in 2021 due to higher employee compensation associated with the hiring of additional personnel and an increase in consulting and other expenses to support our late-stage development of seladelpar in PBC. - Net loss for the three months ended
March 31, 2022 and 2021 was$27.8 million and$17.6 million , or ($0.32 ) and ($0.25 ) per diluted share, respectively. Net loss was higher largely due to increases in clinical operating expenses, as clinical activity related to our late-stage development of seladelpar in PBC continued to expand and accretion of interest expense related to the Abingworth development financing arrangement. We expect our operating expenses to increase in the future as we continue to execute on our clinical development plans.
Conference Call Details
CymaBay will host a conference call today at
About CymaBay
Cautionary Statements
Any statements made in this press release and accompanying conference call regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, CymaBay’s expectations and plans regarding its current and future clinical trials, including the timing of enrollment in RESPONSE, the impact of the COVID pandemic on the enrollment timeline for CymaBay’s clinical trials and CymaBay’s ability to fund current and planned clinical trials are forward-looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of seladelpar could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay's product development activities, including clinical trials; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of CymaBay's product candidates in
For additional information about CymaBay, visit www.cymabay.com.
Public Relations Contact:
(973) 818-8198
Glenn.silver@finnpartners.com
Investor Relations Contact:
(617) 430-7578
Hans@LifeSciAdvisors.com
Financial Results | ||||||||
(In thousands, except share and per share information) | ||||||||
Quarter Ended | ||||||||
2022 | 2021 | |||||||
(unaudited) | (unaudited) | |||||||
Operating expenses: | ||||||||
Research and development | $ | 18,415 | $ | 12,382 | ||||
General and administrative | 6,087 | 5,236 | ||||||
Total operating expenses | 24,502 | 17,618 | ||||||
Loss from operations | (24,502 | ) | (17,618 | ) | ||||
Other income (expense), net: | ||||||||
Interest income | 98 | 67 | ||||||
Interest expense | (3,365 | ) | - | |||||
Total other income (expense), net | (3,267 | ) | 67 | |||||
Net loss | $ | (27,769 | ) | $ | (17,551 | ) | ||
Basic and diluted net loss per common share | $ | (0.32 | ) | $ | (0.25 | ) | ||
Weighted average common shares | ||||||||
outstanding used to calculate | ||||||||
basic and diluted net loss per common share | 87,802,939 | 68,946,092 | ||||||
Balance Sheet Data | ||||||||
(in thousands) | ||||||||
2022 | 2021 | |||||||
(unaudited) | ||||||||
Cash, cash equivalents and marketable securities | $ | 193,444 | $ | 194,602 | ||||
Working capital | 178,007 | 172,733 | ||||||
Total assets | 200,642 | 202,318 | ||||||
Total liabilities | 93,261 | 69,381 | ||||||
Common stock and additional paid-in capital | 902,225 | 899,806 | ||||||
Total stockholders’ equity | 107,381 | 132,937 | ||||||
Source:
2022 GlobeNewswire, Inc., source